Because of selective expression in tumor but not normal tissues, for over a decade, BIRC5 has drawn considerable attention as a potential novel drug target in a variety of human cancers and has consistently been demonstrated to be a critical factor in tumor progression (13). Here, BIRC5 is linked to neoplasm.